What Is Retatrutide Made Of? Structure Explained

Retatrutide is a synthetic peptide under clinical investigation for obesity and type 2 diabetes, with no marketing authorisation in the UK or elsewhere as of October 2026. Understanding what retatrutide is made of requires looking at its molecular structure: a chemically modified amino acid chain designed to activate three distinct hormone receptors simultaneously. This article explains the molecule's composition, its pharmacological targets, what clinical trials have reported so far, and its current regulatory status in the UK, so that anyone seeking factual information can find it in one place.

What is retatrutide and how does it work in the body?

Retatrutide is an investigational synthetic peptide triple agonist with no UK marketing authorisation, designed to act on three hormonal receptor systems to influence appetite, glucose regulation and energy expenditure.

Retatrutide is a synthetic peptide molecule under clinical investigation for the treatment of obesity and type 2 diabetes, with no marketing authorisation in the UK or anywhere else as of October 2026.^[9][8] It belongs to a class of medicines known as incretin-based therapies, which mimic naturally occurring gut hormones that regulate appetite, insulin secretion and energy balance. Unlike earlier medicines in this class, retatrutide is designed to act on three distinct hormonal receptor systems simultaneously, which is why it is sometimes described in the scientific literature as a triple agonist.

In the body, incretin hormones are released from the gut in response to food intake and send signals to the brain, pancreas and other organs to coordinate metabolic responses. Based on findings from early-phase clinical trials, retatrutide's multi-receptor mechanism appears to influence appetite suppression, glucose regulation and energy expenditure across several pathways at once. The full picture of how the medicine behaves in diverse human populations continues to be studied within authorised clinical trials.

Because retatrutide holds no UK marketing authorisation, it is not available through any pharmacy, clinic or prescriber outside of an authorised clinical trial. Anyone who encounters a product sold online under this name should be aware that it cannot be a licensed medicine and may be falsified or unsafe. Licensed weight-management treatments do exist and can be discussed with a GP.

The molecular structure and active ingredients of retatrutide

Retatrutide's active ingredient is a single acylated synthetic peptide chain derived from GLP-1, GIP and glucagon structures; acylation extends its half-life to allow once-weekly dosing in trials.

Retatrutide is made of a single synthetic peptide chain, meaning its active ingredient is a sequence of amino acids engineered to mimic and activate specific hormone receptors in the human body. The molecule is derived from the structure of naturally occurring gut hormones, particularly glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon, and has been chemically modified to enhance its stability, potency and duration of action compared with the native hormones.

A key structural feature described in the scientific literature is the attachment of a fatty acid chain to the peptide backbone. This modification, known as acylation, is understood to allow the molecule to bind to albumin (a protein naturally present in the blood), which slows its breakdown and extends its half-life sufficiently to support once-weekly subcutaneous administration in clinical trials.^[1][3] This approach to prolonging activity is shared with other peptide medicines in the incretin class, though the specific amino acid sequence and acylation pattern of retatrutide are distinct.

The active substance is a single synthetic peptide. Clinical-trial formulations include excipients such as buffers and stabilisers to maintain the peptide's integrity in solution. Full excipient details are governed by trial protocols and are not publicly listed in a UK summary of product characteristics (SmPC), as no such document exists for an investigational medicine. These excipients are not considered active ingredients.

What receptors does retatrutide target compared to other peptides?

Retatrutide targets the GLP-1, GIP and glucagon receptors simultaneously, distinguishing it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP only).

Retatrutide targets three hormone receptors simultaneously: the GLP-1 receptor, the GIP receptor and the glucagon receptor, distinguishing it from currently authorised medicines in the incretin class. For comparison, semaglutide (the active ingredient in Wegovy and Ozempic) acts selectively on the GLP-1 receptor alone, making it a single agonist.^[6][17] Tirzepatide (Mounjaro), which is authorised by the MHRA both for type 2 diabetes and for chronic weight management, targets both the GLP-1 and GIP receptors, making it a dual agonist.^[4][5] Retatrutide's additional action at the glucagon receptor is the principal structural difference in its pharmacological profile.

Each receptor plays a distinct role in metabolic regulation:

• GLP-1 receptor activation slows gastric emptying, reduces appetite and stimulates glucose-dependent insulin secretion.^[17][6]

• GIP receptor activation also supports insulin secretion and may influence fat metabolism and energy storage.

• Glucagon receptor activation increases energy expenditure and promotes the breakdown of stored fat (lipolysis) and glucose release from the liver.^[14][15]

Glucagon itself raises blood glucose, which introduces pharmacological complexity. In clinical trials of retatrutide conducted in people with type 2 diabetes, net glycaemic control improved (as measured by reductions in HbA1c), suggesting that the insulin-stimulating effects of GLP-1 and GIP receptor activation offset the glucose-raising potential of glucagon receptor activity in the populations studied. How this balance performs across different patient populations, including those with varying degrees of insulin resistance, remains an active area of investigation within the ongoing TRIUMPH and TRANSCEND clinical trial programmes. No head-to-head comparisons with licensed medicines have been conducted, and trial findings cannot be directly compared across different study populations and designs.

What have clinical trials reported about retatrutide so far?

Phase 2 and Phase 3 trial data show adverse effects consistent with the incretin class; the full evidence base from the TRIUMPH and TRANSCEND programmes continues to accumulate.

Clinical trial findings for retatrutide have been reported from Phase 2 studies and from the Phase 3 TRIUMPH and TRANSCEND programmes, though the full body of evidence continues to accumulate. The Phase 2 data, published in the New England Journal of Medicine in 2023, examined retatrutide in adults with obesity over 48 weeks and reported substantial reductions in body weight compared with placebo at higher doses. A separate Phase 2 trial in adults with type 2 diabetes was also published in 2023.^[2][14] Phase 3 readouts from the TRANSCEND and TRIUMPH programmes have been presented at major diabetes and obesity congresses; peer-reviewed publications from these programmes are expected to provide more definitive evidence across broader populations.

As with all investigational medicines, these results must be interpreted within the context of the specific trial populations, durations and conditions under which they were obtained. Phase 2 trials are designed primarily to assess safety, tolerability and dose-finding rather than to provide definitive evidence of efficacy across broad populations.

The safety findings from trials to date have identified adverse effects consistent with the incretin class, including nausea, vomiting, diarrhoea and constipation, which were generally more common at higher doses and during dose escalation.^[1][2] An increase in resting heart rate has been observed, consistent with findings seen with other GLP-1-based medicines; these findings are being monitored in ongoing studies.^[15][16] Pancreatitis has been reported as a potential concern across the incretin class more broadly, and trial participants are monitored accordingly. Retatrutide trials exclude participants who are pregnant, breastfeeding or planning pregnancy, and contraception requirements apply to trial participants of childbearing potential. These exclusions reflect standard practice for investigational medicines where reproductive safety data are not yet established.

What is retatrutide's current regulatory status in the UK?

Retatrutide has no UK marketing authorisation from the MHRA and can only be lawfully received through participation in an authorised clinical trial.

Retatrutide does not hold a marketing authorisation in the UK, and no date can be given for when or whether one will be granted. In the UK, medicines are authorised by the Medicines and Healthcare products Regulatory Agency (MHRA), which evaluates safety, quality and efficacy data submitted by a manufacturer before a medicine can be legally marketed or prescribed outside of a clinical trial.^[8][9] Until that process is complete and authorisation is granted, retatrutide cannot be supplied through any pharmacy, clinic or prescriber in the UK.

The only lawful route through which a person in the UK could receive retatrutide is participation in an authorised clinical trial operating under a valid clinical trial authorisation. Eligibility for such trials is determined by strict inclusion and exclusion criteria set by the trial protocol, and participation involves informed consent, regular monitoring and adherence to the study procedures. Trials are registered on public databases such as ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS), where details of ongoing studies can be found.

If you are participating in a clinical trial involving retatrutide, any suspected adverse effects or urgent health concerns should be reported to your study team in accordance with the trial protocol. You should carry your trial participant card or information sheet at all times and inform any emergency clinician that you are enrolled in a clinical trial.

Anyone who encounters retatrutide offered for sale online, through a clinic or via any other route outside of a formal clinical trial should treat this with serious caution. Such a product cannot be a licensed medicine in the UK and may be counterfeit, contaminated or otherwise unsafe. If you have concerns about a product you have been offered or have taken, contact your GP or, for urgent concerns, NHS 111. Suspected adverse reactions to medicines encountered outside of licensed supply chains can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions